2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1497

Panlar Consensus on Hand, Hip and Knee OA
Abstract Number: 1498

Engaging Clinic Staff in Work System Redesign to Adapt a Hypertension Protocol for Rheumatology
Abstract Number: 1499

Patients Who Take Many Medications for Their Fibromyalgia Symptoms at the Initial Office Visit Tend to Have a Worse Clinical Course
Abstract Number: 1500

Impact of Menopause on Functional Impairment of Rheumatoid Arthritis Patients
Abstract Number: 1501

Prevalence of Unassessed and Uncontrolled Cardiovascular Disease Risk Factors Among Rheumatoid Arthritis Patients in an Academic Rheumatology Practice
Abstract Number: 1502

Initiating Statin Medication and Risk of Fatigue in Rheumatoid Arthritis
Abstract Number: 1503

A Systematic Screening of Comorbidities By the Rheumatologist in Inflammatory Rheumatisms Impacts Chronic Disease Care
Abstract Number: 1504

Increased Risk of Thromboembolism Among Patients with VTE Association with Rheumatoid Arthritis
Abstract Number: 1505

Carotid Artery Atherosclerosis in Patients with Active Rheumatoid Arthritis: Predictors of Plaque Occurrence and Progression over 24 Weeks
Abstract Number: 1506

EULAR Recommendations for Cardiovascular Risk Management in Patients with Rheumatoid Arthritis and Other Inflammatory Joint Diseases – 2015 Update
Abstract Number: 1507

Risk of Obstructive Sleep Apnea in Rheumatoid Arthritis Patients: The Frequency and Associated Disease Features
Abstract Number: 1508

Lipid Target Achievement Among Patients with Recent-Onset Rheumatoid Arthritis during the First Six Years of Follow-up: Results from a French Multicenter Cohort of Early Arthritis
Abstract Number: 1509

Serum Nitrite Levels in Rheumatoid Arthritis and Relationship to Cardiovascular Risk Factors and Atherosclerosis Biomarkers
Abstract Number: 1510

The Association Between HDL Cholesterol Efflux Capacity, Citrullinated ApoA1 and Anti-Citrullinated ApoA1 Antibodies in Rheumatoid Arthritis
Abstract Number: 1511

Increased Prevalence of Anti-Nuclear and Anti-SSA Autoantibodies in African American Rheumatoid Arthritis Patients Versus Matched Caucasian Rheumatoid Arthritis Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].